Response Oncology Performance
The company holds a Beta of 0.0, which implies not very significant fluctuations relative to the market. the returns on MARKET and Response Oncology are completely uncorrelated.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Response Oncology has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fairly strong forward indicators, Response Oncology is not utilizing all of its potentials. The latest stock price disturbance, may contribute to short-term losses for the investors. ...more
| Total Cashflows From Investing Activities | 10000.00 |
Response |
Response Oncology Relative Risk vs. Return Landscape
If you would invest (100.00) in Response Oncology on September 19, 2024 and sell it today you would earn a total of 100.00 from holding Response Oncology or generate -100.0% return on investment over 90 days. Response Oncology is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of stocks are less volatile than Response, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Response Oncology Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Response Oncology's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Response Oncology, and traders can use it to determine the average amount a Response Oncology's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| ROIX |
Based on monthly moving average Response Oncology is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Response Oncology by adding Response Oncology to a well-diversified portfolio.
Response Oncology Fundamentals Growth
Response Stock prices reflect investors' perceptions of the future prospects and financial health of Response Oncology, and Response Oncology fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Response Stock performance.
| Return On Equity | -7.24 | |||
| Return On Asset | -0.0153 | |||
| Profit Margin | (0.47) % | |||
| Operating Margin | (0.01) % | |||
| Current Valuation | 16.62 M | |||
| Shares Outstanding | 12.18 M | |||
| Revenue | 118.08 M | |||
| EBITDA | 1.32 M | |||
| Cash And Equivalents | 9.01 M | |||
| Cash Per Share | 0.74 X | |||
| Total Debt | 26.45 M | |||
| Book Value Per Share | (1.54) X | |||
| Cash Flow From Operations | 9.1 M | |||
| Earnings Per Share | (4.16) X | |||
| Total Asset | 28.9 M | |||
| Retained Earnings | (120.16 M) | |||
| Current Asset | 37.25 M | |||
| Current Liabilities | 2.54 M | |||
About Response Oncology Performance
Evaluating Response Oncology's performance through its fundamental ratios, provides valuable insights into its operational efficiency and profitability. For instance, if Response Oncology has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Response Oncology has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements. Please also refer to our technical analysis and fundamental analysis pages.
Response Oncology, Inc. does not have significant operations. Prior to the sale of its assets, it provided advanced cancer treatment services through outpatient facilities known as IMPACT Centers under the direction of practicing oncologists owned the assets of and managed the nonmedical aspects of oncology practices compounded and dispensed pharmaceuticals to certain oncologists for a fixed or cost plus fee and conducted outcomes research on behalf of pharmaceutical manufacturers. Response Oncology is traded on OTC Exchange in the United States.Things to note about Response Oncology performance evaluation
Checking the ongoing alerts about Response Oncology for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Response Oncology help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Response Oncology is not yet fully synchronised with the market data | |
| Response Oncology has some characteristics of a very speculative penny stock | |
| Response Oncology has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 118.08 M. Net Loss for the year was (51.39 M) with profit before overhead, payroll, taxes, and interest of 28.17 M. |
- Analyzing Response Oncology's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Response Oncology's stock is overvalued or undervalued compared to its peers.
- Examining Response Oncology's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Response Oncology's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Response Oncology's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Response Oncology's stock. These opinions can provide insight into Response Oncology's potential for growth and whether the stock is currently undervalued or overvalued.
Check out Your Equity Center to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in gross domestic product. You can also try the Money Flow Index module to determine momentum by analyzing Money Flow Index and other technical indicators.
Other Consideration for investing in Response Stock
If you are still planning to invest in Response Oncology check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Response Oncology's history and understand the potential risks before investing.
| Efficient Frontier Plot and analyze your portfolio and positions against risk-return landscape of the market. | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Equity Forecasting Use basic forecasting models to generate price predictions and determine price momentum | |
| Bonds Directory Find actively traded corporate debentures issued by US companies | |
| Watchlist Optimization Optimize watchlists to build efficient portfolios or rebalance existing positions based on the mean-variance optimization algorithm | |
| My Watchlist Analysis Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like | |
| Crypto Correlations Use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins | |
| Portfolio Suggestion Get suggestions outside of your existing asset allocation including your own model portfolios |